Privately held Kommanditgesellschaft with an Aktiengesellschaft as general partner
Industry
Pharmaceuticals
Founded
1885; 139 years ago (1885) in Ingelheim am Rhein, Germany
Founder
Albert Boehringer
Headquarters
Ingelheim
,
Germany
Area served
Worldwide
Key people
Hubertus von Baumbach, Chairman of the board,
Michael Schmelmer, board member (CFO)
Carinne Brouillon, board member
Jean Scheftsik de Szolnok, board member
Michel Pairet, board member
Shashank Deshpande, board member
Paola Casarosa, board member[1]
Products
Pharmaceuticals and Animal Health
Revenue
€25.6 billion (2023)[2]
Owner
Boehringer, Liebrecht and von Baumbach families
Number of employees
53,565 (2023)[2]
Website
boehringer-ingelheim.com
C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families.[3] The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.[4]
^"Board of Directors". boehringer-ingelheim.com. Retrieved 17 October 2023.
C.H. Boehringer Sohn AG & Co. KG is the parent company of the BoehringerIngelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in...
BoehringerIngelheim Animal Health is a multinational animal health company, formed in January 2017 when Merial was acquired by BoehringerIngelheim and...
Mainz-Bingen. Furthermore, Ingelheim harbours the business BoehringerIngelheim which is active worldwide. In 2004, 36% of Ingelheim's inhabitants belonged...
Boehringer (Böhringer) may refer to: BoehringerIngelheim, a pharmaceutical company Boehringer Laboratories, an American medical technology company Boehringer...
excessive mucus. It was developed in the research laboratory of BoehringerIngelheim in the late 1950s as an active ingredient for pharmaceutical use...
chairman and CEO of BoehringerIngelheim, Germany's second largest pharmaceutical company. The son of Erich von Baumbach and Ulrike Boehringer, Hubertus von...
{h}}]}{{\text{output per step}}[{\ce {kg}}]}}} The process chemistry group at BoehringerIngelheim, for example, targets a VTO of less than 1 for any given synthetic...
inhibitor (NDRI). It was first developed in the 1960s by a team at BoehringerIngelheim. Its activity at the dopamine transporter is six times stronger than...
the biggest draw back of the jet nebulizer. The medical company BoehringerIngelheim also invented a device named Respimat Soft Mist Inhaler in 1997....
Ponazuril (INN), sold by Merial, Inc., now part of BoehringerIngelheim, under the trade name Marquis® (15% w/w ponazuril), is a drug currently approved...
in the city, including Eli Lilly and Company, Procter & Gamble, BoehringerIngelheim, and Nestlé. The city is the point of origin and namesake of Kobe...
for medical use in the United States in 2000. It was developed by BoehringerIngelheim; however, it is also available as a generic medication. In 2021,...
teach at the university and starting in 1907 was a consultant for BoehringerIngelheim.[citation needed] In 1914 he became associate professor for special...
Metformin, sold under the brand name Glucophage, among others, is the main first-line medication for the treatment of type 2 diabetes, particularly in...
while BoehringerIngelheim could receive more than $800 million from development of the new drugs. Oral anti-diabetic of BoehringerIngelheim–Linagliptin...
Johannes Gutenberg University in Mainz, Germany. It is funded by the BoehringerIngelheim Foundation and the state of Rheinland Palatinate. The scientists...
disease (COPD), and other respiratory conditions. Its developer, BoehringerIngelheim, is currently[when?] conducting approved in the U.S. with a variety...
analog rather than an analog of oxyntomodulin. It is developed by BoehringerIngelheim as a weight loss drug. Klein, Thomas; Augustin, Robert; Hennige,...
and platelet derived growth factor receptor. Ofev was developed by BoehringerIngelheim. It received U.S. Food and Drug Administration (FDA) approval for...
SGLT-2 over SGLT-1, SGLT-4, SGLT-5 and SGLT-6. It was developed by BoehringerIngelheim and is co-marketed by Eli Lilly and Company. It is also available...
United States in August 2014, under the brand name Jardiance by BoehringerIngelheim. Of the gliflozins, empagliflozin and tofogliflozin have the highest...
"CATAPRES® 150 TABLETS CATAPRES® AMPOULES" (PDF). TGA eBusiness Services. BoehringerIngelheim Pty Limited. 28 February 2013. Archived from the original on 16 January...
chronic obstructive pulmonary disease (COPD). It is manufactured by BoehringerIngelheim. Olodaterol is a once-daily maintenance bronchodilator treatment...
July 2014, a series of investigations accused the privately held BoehringerIngelheim pharmaceutical group of withholding critical information about the...
UK. It is marketed by various companies under licence, including BoehringerIngelheim and CSL. Tamsulosin hydrochloride extended-release capsules are marketed...
bronchodilator asthma medication. Fenoterol is produced and sold by BoehringerIngelheim as Berotec N and in combination with ipratropium as Berodual N. It...
Global Information
€25.6 billion (2023)[2]